Alpelisib(BYL719)选择性抑制PI3Kα在PIK3CA突变实体瘤中的首次人体研究
该首次人体Ia期研究评估了口服PI3Kα选择性抑制剂Alpelisib在PIK3CA突变晚期实体瘤患者中的最大耐受剂量、安全性和初步疗效。
要点
- Alpelisib最大耐受剂量为400mg每日一次或150mg每日两次。
- 常见治疗相关不良事件包括高血糖(51.5%)和恶心(50.0%)。
- PIK3CA突变实体瘤客观缓解率6.0%,疾病控制率58.2%。
核心结论
- Alpelisib在PIK3CA突变实体瘤中安全性可耐受,并显示出鼓舞人心的初步抗肿瘤活性。
研究设计与样本
- 剂量递增阶段纳入PIK3CA突变晚期实体瘤患者,接受每日一次或每日两次口服Alpelisib。
- 剂量扩展阶段纳入PIK3CA突变实体瘤患者及PIK3CA野生型雌激素受体阳性/人表皮生长因子受体2阴性乳腺癌患者,接受Alpelisib 400mg每日一次。
主要发现
- 剂量递增阶段9例(13.2%)出现剂量限制性毒性:高血糖(6例)、恶心(2例)、高血糖合并低磷血症(1例)。
- 常见全等级治疗相关不良事件:高血糖(51.5%)、恶心(50.0%)、食欲下降(41.8%)、腹泻(40.3%)、呕吐(31.3%)。
- Alpelisib吸收迅速,400mg每日一次时半衰期为7.6小时,蓄积极少。
- 客观肿瘤缓解见于剂量≥270mg每日一次;总缓解率6.0%(8例,其中1例子宫内膜癌完全缓解,7例宫颈癌、乳腺癌、子宫内膜癌、结肠癌和直肠癌部分缓解)。
- 70例(52.2%)达到疾病稳定,其中13例(9.7%)维持稳定超过24周;疾病控制率58.2%。
临床怎么用
- Alpelisib在PIK3CA突变实体瘤中显示出可耐受的安全性和初步活性,支持进一步研究PI3Kα选择性抑制与其他药物联合治疗PIK3CA突变肿瘤。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Purpose We report the first-in-human phase Ia study to our knowledge ( ClinicalTrials.gov identifier: NCT01219699) identifying the maximum tolerated dose and assessing safety and preliminary efficacy of single-agent alpelisib (BYL719), an oral phosphatidylinositol 3-kinase α (PI3Kα)-selective inhibitor. Patients and Methods In the dose-escalation phase, patients with PIK3CA-altered advanced solid tumors received once-daily or twice-daily oral alpelisib on a continuous schedule. In the dose-expansion phase, patients with PIK3CA-altered solid tumors and PIK3CA-wild-type, estrogen receptor-positive/human epidermal growth factor receptor 2-negative breast cancer received alpelisib 400 mg once daily. Results One hundred thirty-four patients received treatment. Alpelisib maximum tolerated doses were established as 400 mg once daily and 150 mg twice daily. Nine patients (13.2%) in the dose-escalation phase had dose-limiting toxicities of hyperglycemia (n = 6), nausea (n = 2), and both hyperglycemia and hypophosphatemia (n = 1). Frequent all-grade, treatment-related adverse events included hyperglycemia (51.5%), nausea (50.0%), decreased appetite (41.8%), diarrhea (40.3%), and vomiting (31.3%). Alpelisib was rapidly absorbed; half-life was 7.6 hours at 400 mg once daily with minimal accumulation. Objective tumor responses were observed at doses ≥ 270 mg once daily; overall response rate was 6.0% (n = 8; one patient with endometrial cancer had a complete response, and seven patients with cervical, breast, endometrial, colon, and rectal cancers had partial responses). Stable disease was achieved in 70 (52.2%) patients and was maintained > 24 weeks in 13 (9.7%) patients; disease control rate (complete and partial responses and stable disease) was 58.2%. In patients with estrogen receptor-positive/human epidermal growth factor receptor 2-negative breast cancer, median progression-free survival was 5.5 months. Frequently mutated genes (≥ 10% tumors) included TP53 (51.3%), APC (23.7%), KRAS (22.4%), ARID1A (13.2%), and FBXW7 (10.5%). Conclusion Alpelisib demonstrated a tolerable safety profile and encouraging preliminary activity in patients with PIK3CA-altered solid tumors, supporting the rationale for selective PI3Kα inhibition in combination with other agents for the treatment of PIK3CA-mutant tumors.
引用
- Juric D, Rodon J, Tabernero J, et al. Phosphatidylinositol 3-Kinase α-Selective Inhibition With Alpelisib (BYL719) in PIK3CA-Altered Solid Tumors: Results From the First-in-Human Study. J Clin Oncol. 2018. PMID: 29401002. doi:10.1200/JCO.2017.72.7107
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。